Antibodies are increasingly important in medical diagnostics and in the treatment of a broad range of disease states including cancer, inflammation and auto-immune diseases. Through antibody drug conjugates (ADCs), antibodies also enable the targeted delivery of traditional drugs. In contrast to traditional chemotherapeutic agents, ADCs target and attack the cancer cells so that healthy cells are less severely affected.
Many critical properties of antibodies cannot be predicted from sequence alone, or can be predicted more accurately with access to a 3D antibody structure.
Improving the understanding of these properties as early as possible in development and formulation will impact speed and total cost to market. When 3D structures are not available from X-RAY or NMR, 3D in silico models generated by BIOVIA Discovery Studio are the solution.